RARE DISEASE COMPANY COALITION
RARE DISEASE COMPANY COALITION
GS
Background
Career
RD
Washington, DC · current
Government experience
Legislative Intern
Sen. Lamar Alexander.
Covered official positions, as disclosed on federal filings
The past 12 months
Clients
1
past 12 months
Filings
2
past 12 months
Agencies contacted
HOUSE OF REPRESENTATIVESSENATECenters For Medicare and Medicaid Services (CMS)
Specific issues
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Proclamation 11020 - Section 232 Pharmaceutical Tariffs
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗